Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...
On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $49.25 which represents a decrease of $-0.05 or -0.10% from the prior close of $49.3. The stock opened at $49.35 ...
J.P. Morgan analyst Jessica Fye maintained a Hold rating on Alkermes (ALKS – Research Report) yesterday and set a price target of $26.00.
Get the latest Australian and world news covering breaking news and trending topics that educate, engage and entertain. Learn more about where you live, the language you speak, and how the country ...
For many years, Kim Jong Un was roundly dismissed by many Western leaders as a serious threat to peace and stability on the world stage despite his sabre-rattling rhetoric and promises of nuclear ...
Oct. 25, 2024 — Research shows that the breast cancer gene 1 (BRCA1) not only pushes accurate DNA repair to guard against cancer but promotes subsequent activity in tumor ... Researchers Develop ...
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 23, 2024. REUTERS/Brendan McDermid/File Photo The Nasdaq ended higher on Friday, driven by megacap ...
“We are not intimidated by them and that’s why they are using everything in their ammunition to silence us.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback